Expertise in
36
conditions

Dr. Amanda L. Jackson

Obstetrics and Gynecology
234 Goodman Street, Floor 3, 
Cincinnati, OH 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
36
conditions
234 Goodman Street, Floor 3, 
Cincinnati, OH 

Overview

Amanda Jackson is an Obstetrics and Gynecologist in Cincinnati, Ohio. Dr. Jackson is highly rated in 36 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Hysterectomy, and Intrauterine Device Insertion.

Her clinical research consists of co-authoring 44 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Medical University Of South Carolina, 2007

Residency

Brown University/Women & Infants Hospital Of Ri, Obstetrics & Gynecology, 2011

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in RI

Fellowships

University Of North Carolina At Chapel Hill, Gynecologic Oncology, 2014

Hospital Affiliations

Mercy Health - Fairfield Hospital
Mercy Health - West Hospital
The Jewish Hospital - Mercy Health
Mercy Health - Anderson Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

University of Cincinnati Physicians
234 Goodman Street, Floor 3, Cincinnati, OH 45219

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Enrollment Status: Recruiting
Publish Date: January 14, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin
Study Phase: Phase 1/Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Drug
Study Drug: STRO-002
Study Phase: Phase 1
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
Safety Study of Bintrafusp Alfa in Combination With Other Anti-cancer Therapies in Participants With Locally Advanced or Advanced Cervical Cancer (INTR@PID 046)
Safety Study of Bintrafusp Alfa in Combination With Other Anti-cancer Therapies in Participants With Locally Advanced or Advanced Cervical Cancer (INTR@PID 046)
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Drug, Radiation
Study Drugs: Bintrafusp Alfa, Carboplatin, Paclitaxel, Bevacizumab, Cisplatin
Study Phase: Phase 1
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Bintrafusp Alfa
Study Phase: Phase 2
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: July 25, 2023
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
View 8 Less Clinical Trials

44 Total Publications

Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability.
Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability.
Journal: Gynecologic oncology
Published: June 11, 2025
Similar Doctors
Thomas Herzog
Expertise in
25
conditions
Dr. Thomas Herzog
Obstetrics and Gynecology
Expertise in
25
conditions
Dr. Thomas Herzog
Obstetrics and Gynecology

University Of Cincinnati Physicians Company-Ob/Gyn

3188 Bellevue Ave Ste 100, 
Cincinnati, OH 
 (10.5 miles away)
513-584-6373
Languages Spoken:
English
See accepted insurances

Thomas Herzog is an Obstetrics and Gynecologist in Cincinnati, Ohio. Dr. Herzog is highly rated in 25 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy.

Expertise in
16
conditions
Dr. Christine Pennesi
Obstetrics and Gynecology
Expertise in
16
conditions
Dr. Christine Pennesi
Obstetrics and Gynecology

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (11.7 miles away)
513-636-9400
Languages Spoken:
English
See accepted insurances

Christine Pennesi is an Obstetrics and Gynecologist in Cincinnati, Ohio. Dr. Pennesi is highly rated in 16 conditions, according to our data. Her top areas of expertise are Kuster Syndrome, Mayer-Rokitansky-Kuster-Hauser Syndrome, Mullerian Aplasia, Intrauterine Device Insertion, and Oophorectomy.

Expertise in
13
conditions
Dr. Carri Warshak
Obstetrics and Gynecology
Expertise in
13
conditions
Dr. Carri Warshak
Obstetrics and Gynecology

Uc Health Obgyn-Midtown Physicians Office Building (Uc Medical Center)

3590 Lucille Dr, 
Cincinnati, OH 
 (16.3 miles away)
513-475-8588
Languages Spoken:
English
See accepted insurances

Carri Warshak is an Obstetrics and Gynecologist in Cincinnati, Ohio. Dr. Warshak is highly rated in 13 conditions, according to our data. Her top areas of expertise are Preeclampsia, HELLP Syndrome, Eclampsia, and Premature Infant.

Frequently Asked Questions about Dr. Amanda L. Jackson

How do I make an appointment with Dr. Amanda L. Jackson?

You can book an appointment with Dr. Amanda L. Jackson by calling their office at 513-584-6373. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Amanda L. Jackson a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Amanda L. Jackson is classified as an Elite expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Amanda L. Jackson specialize in?

While Dr. Amanda L. Jackson is a Obstetrics and Gynecology, they have specific expertise in Endometrial Cancer, Cervical Cancer, and Ovarian Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. Amanda L. Jackson participate in research or clinical trials?

Yes. Dr. Amanda L. Jackson has published 44 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Amanda L. Jackson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Amanda L. Jackson accept my insurance?

Dr. Amanda L. Jackson accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 513-584-6373 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jackson's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 23 Advanced Conditions
View All 56 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile